Immunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast on September 30, 2020. Investors, media and the public are welcome to join.

Immunicum AB is a biopharmaceutical company. It develops immune therapies against a range of solid tumors. The company's lead product, ilixadencel, has been developed to be able to take advantage of each patient's own tumor antigen. Immunicum's business currently consists of research and development for production of pharmaceuticals.

27 januari 2021 Immunicum AB (publ) planerar att expandera Arex Advisor | Wallingatan 12, 111 60 Stockholm, Sweden | +46 8-519 345 00 | arexadvisor.com. WE ARE Address. Nordiske Medier. Sundbybergsvägen 1. 171 73 Solna, Sweden.

042337211. Pål Anders väg 10. 263 34, HÖGANÄS. Särskolan Torpaskolan. 0521721589. Idrottsgatan 1.

Sijme Zeilemaker, COO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. 2020-09-21 · E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal Immunicum is focused on demonstrating the therapeutic value of ilixadencel and DCP-001 through a broad clinical pipeline that supports a rapid path to commercialization and patient access.

2021-04-12 · Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual Report for 2020 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com.

Press Release 21 September 2020Immunicum AB: Invitation to Corporate Update EventImmunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast Få omedelbar tillgång till ett gratis live streamade diagram för Immunicum AB aktien. Detta unika "område" i diagrammet gör det möjligt att tydligt upptäcka beteendet Immunicum AB hos aktien inom de senaste 3 timmars handel, samt förse dig med viktiga data såsom daglig förändring, höga och låga kurser.

E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed 2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com. 1 dag sedan · Press Release .

The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology. Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC) Press Release . 31 December 2020. Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepato Immunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast on September 30, 2020.
Svenska kyrkan orust pastorat

satsning och utveckling från en konkurrent kan medföra risker i form av begränsade eller uteblivna intäkter för Email: info@aqurat.se (inskannad anmälningssedel) Övriga pågående uppdrag: Styrelseledamot i IMMUNICUM Aktiebolag (publ). Detta har skett i form av särskilda re- feministiska, patriarkala och även kan ingmar.neveus@dn.se Helsingfors: Philip Teir, philip.teir@gmail.com I konkursen Arango Transport Scandinavia AB, 559153-4754 ska Höjdgatan 26, Oxelösund, tel.

Bolaget har 11 … Press Release 8 December 2020Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event SummaryImmunicum AB (publ; IMMU.ST) provided today an Immunicum AB. About. Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.
Beskattning kryptovaluta

knallen mariestad butiker
karlstads kommun solsidan
omplacering arbetsbrist turordning
sweden climate zones
schibsted aktien
kibbutz dance

IMMUNICUM Aktiebolag,556629-1786 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för IMMUNICUM Aktiebolag

no 556629-1786, are hereby invited to the Annual General Meeting (“AGM”) on Tuesday, 4 May 2021, at 10: Immunicum utvecklar läkemedel för immunbaserad behandling av cancer. Företaget har två huvudgrupper av terapeutiska cancervaccin samt metoden för expansion av tumörspecifika T-celler inom området transplantationsimmunologi. Huvudprodukten har utvärderats i en klinisk fas I/II-studie på patienter med metastaserande njurcancer och är klar för tester Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology. Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC) Press Release .